Evidence map›Paper›PMID 27300146›Full record

ArticleEpilepsy & behavior : E&B2016

High-dose versus low-dose valproate for the treatment of juvenile myoclonic epilepsy: Going from low to high.

Laura E Hernández-Vanegas, Aurelio Jara-Prado, Adriana Ochoa, Nayelli Rodríguez Y Rodríguez, Reyna M Durón, Daniel Crail-Meléndez, Ma Elisa Alonso, Antonio V Delgado-Escueta, Iris E Martínez-Juárez

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Epilepsy & behavior : E&B, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 3 countries.

Laura E Hernández-VanegasNational Institute of Neurology and Neurosurgery of Mexico, Epilepsy Clinic, Mexico.
Aurelio Jara-PradoNational Institute of Neurology and Neurosurgery of Mexico, Neurogenetics and Molecular Biology Department, Mexico.
Adriana OchoaNational Institute of Neurology and Neurosurgery of Mexico, Neurogenetics and Molecular Biology Department, Mexico.
Nayelli Rodríguez Y RodríguezBenemérita Universidad Autónoma de Puebla, Mexico.
Reyna M DurónUniversidad Tecnológica Centroamericana (UNITEC), Tegucigalpa, Honduras.
Daniel Crail-MeléndezNational Institute of Neurology and Neurosurgery of Mexico, Neuropsychiatry Unit, Mexico.
Ma Elisa AlonsoNational Institute of Neurology and Neurosurgery of Mexico, Neurogenetics and Molecular Biology Department, Mexico.
Antonio V Delgado-EscuetaEpilepsy Genetics/Genomics Laboratories and Epilepsy Center of Excellence, Neurology and Research Services, VA GLAHS, Los Angeles, CA, United States; David Geffen School of Medicine at UCLA, Los Angeles, CA, United States.
Iris E Martínez-JuárezNational Institute of Neurology and Neurosurgery of Mexico, Epilepsy Clinic, Mexico. Electronic address: imartinez@innn.edu.mx.
Instituto Nacional de Neurología y Neurocirugía · MXBenemérita Universidad Autónoma de Puebla · MXCentral American Technological University · HNUniversity of California, Los Angeles · US

Funding

Discovering More Juvenile Myoclonic Epilepsy Genes by a ConsortiumR01NS055057 · NINDS · BRENTWOOD BIOMEDICAL RESEARCH INSTITUTE · PI BAILEY, JULIA N, DELGADO-ESCUETA, ANTONIO V. · 2010 to 2014
$2.4M
NINDS NIH HHS R01 NS055057
6 · The paper itself

Abstract

Juvenile myoclonic epilepsy (JME) is a genetic generalized epilepsy accounting for 3-12% of adult cases of epilepsy. Valproate has proven to be the first-choice drug in JME for controlling the most common seizure types: myoclonic, absence, and generalized tonic-clonic (GTC). In this retrospective study, we analyzed seizure outcome in patients with JME using valproate monotherapy for a minimum period of one year. Low valproate dose was considered to be 1000mg/day or lower, while serum levels were considered to be low if they were at or below 50mcg/dl. One hundred three patients met the inclusion criteria. Fifty-six patients (54.4%) were female. The current average age was 28.4±7.4years, while the age of epilepsy onset was 13.6±2.9years. Most patients corresponded to the subsyndrome of classic JME. Forty-six (44.7%) patients were free from all seizure types, and 76 (73.7%) patients were free from GTC seizures. No significant difference was found in seizure freedom among patients using a low dose of valproate versus a high dose (p=0.535) or among patients with low blood levels versus high blood levels (p=0.69). In patients with JME, it seems appropriate to use low doses of valproate (500mg to 1000mg) for initial treatment and then to determine if freedom from seizures was attained.

Indexed as

AdolescentAdultAge of OnsetAnticonvulsantsChildDose-Response Relationship, DrugElectroencephalographyFemaleHumansMaleMiddle AgedMyoclonic Epilepsy, JuvenilePatient ComplianceRetrospective StudiesRisk FactorsTreatment OutcomeAnticonvulsantsValproic AcidAntiepileptic drugsBlood levelDoseEpilepsy/seizuresJuvenile myoclonic epilepsyValproate

Identifiers

PMID27300146
PMCPMC4985524
OpenAlexW2410344646

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.